The anticipated size of the prurigo nodularis treatment market in 2022 was US$ 671.4 million and is estimated to be US$ 693.3 million in 2023. Various non-government organizations with the help of different funding mechanisms, have led to transitional projects which help in enabling an ample amount of financing for the research and development of the market.
Different initiatives like activities and programs have been undertaken for growth in awareness about rare diseases with their available therapeutic options which in turn boosted the demand for prurigo nodularis treatment. According to Future Market Insights Report, the prurigo nodularis treatment market is projected to expand at a CAGR of 3.0% between 2023 and 2033, totaling around US$ 930.9 million by 2033.
The Prurigo nodularis treatment market is experiencing growth due to the rising demand for orphan drugs for the treatment of rare diseases like Prurigo nodularis. Several non-governmental organizations are collaborating with diverse funding mechanisms to facilitate transitional projects that provide adequate financing for research and development in the market.
Various initiatives like awareness activities and programs are expected to increase knowledge about rare diseases and available therapeutic options, thereby driving the demand for prurigo nodularis treatment.
Demand for innovative drugs and preventative therapies to improve patient outcomes is increasing due to the expanding patient population and limited availability of biologics, drugs, and devices for associated disorders. Further, the market for prurigo nodularis therapeutics is anticipated to benefit from the increasing research and development investments aimed at developing orphan drugs for rare health conditions.
The usage of photochemotherapy, cryotherapy, and immunosuppressants for managing prurigo nodularis disease is further expected to propel the market growth during the forecast period.
| Attribute | Details |
|---|---|
| Projected Forecast Value (2022) | US$ 671.4 million |
| Projected Forecast Value (2023) | US$ 693.3 million |
| Projected Forecast Value (2033) | US$ 930.9 million |
| Growth rate | 3.0% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global prurigo nodularis treatment market grew at a CAGR of 2.8% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 3.0% between 2023 and 2033.
The market for prurigo nodularis treatment benefits from a diverse range of available options, including both topical and oral medications. Patients and healthcare providers can choose from multiple treatment options that suit their specific needs. Ongoing research, such as the development of monoclonal antibodies and other biologic therapies, holds promise for improving patient outcomes.
Advancements in medical technology have led to the introduction of new and innovative treatment options, such as advanced phototherapy methods, providing patients with many choices.
The usage of emollients to treat prurigo nodularis is expected to generate new growth opportunities for the market in the coming years. Emollients offer numerous benefits, including their ability to effectively soothe and heal dry skin. Further, the increase in the prevalence of prurigo nodularis has led to a high demand for effective medications that provide better and quick outcomes. These medications are particularly helpful in improving the appearance and health of the skin, thereby driving the demand for these drugs.
Flexible and easy regulatory guidelines governing the use of orphan drugs for treating prurigo nodularis are expected to shape the demand outlook for treatment drugs during the forecast period. With their well-established supply chain activities for cross-border trading, retail pharmacies are the primary distribution channel for supplying drugs for managing prurigo nodularis disorder which is expected to drive market growth in the forthcoming years further. Moreover, increasing adoption of e-commerce, online pharmacies are expected to witness significant growth which is further expected to fuel market growth in the forthcoming years.
Innovations in New Treatment Options to Drive Market Growth
The rising prevalence of conditions like prurigo nodularis and bacterial infections, coupled with an increase in patients, is expected to drive market growth. Key market players are primarily focusing on the population aged between 20 to 60 years, as well as patients with human immune deficiency virus and atopic dermatitis since they are susceptible to these diseases.
An increase in awareness about treatment options among the population is likely to drive market growth. Additionally, various innovations in the field of treatment are also expected to create new opportunities for market expansion. Further, regulatory bodies are continuously striving to create favorable outcomes for the development and commercialization of orphan drugs for patients with rare diseases. Such regulations help accelerate the development and approval process of investigational drugs.
Increasing Demand for Capsaicin Cream is Fueling the Market Growth
Burgeoning demand for capsaicin cream is further anticipated to propel market growth. Capsaicin cream is estimated to account for a significant share of the global market among different drug classes during the projection period as there is increasing demand for topical drugs that are easy to apply and highly effective. Consequently, increasing demand for capsaicin cream is thus expected to contribute to the growth of the prurigo nodularis treatment market.
Principal Consultant
Lack of Awareness about the Disease to Restrain Market Expansion
The dearth of awareness about rare diseases like prurigo nodularis and the available treatment options is expected to hinder the market growth. Poor economic conditions and healthcare infrastructure in some countries impede the adoption of prurigo nodularis treatment. Further, market growth is limited due to the heavy reliance of emerging economies on developed nations for raw materials, skilled labor, advanced technology therapeutics, and drugs.
Germany Driving Growth with a Significant CAGR
Europe prurigo nodularis treatment market accounted for a revenue share of 58.6% in 2022. Germany is expected to dominate the regional market by expanding at a CAGR of 5.1% during the forecast period. The dominant position of Germany in the market can be attributed to the presence of leading market players and significant government-led research and development initiatives in the region.
Rising Rate of Approval and Commercialization of Drugs in the United Kingdom
The United Kingdom is said to hold a profitable market during the forecast period, driven by the increasing prevalence of prurigo nodularis disorder in the region expanding at a CAGR of 2.1% in the market. Moreover, the increasing rate of approval and commercialization of drugs for prurigo nodularis treatment in this region is expected to fuel market growth. The majority of key players have their headquarters based in the United Kingdom, which is expected to induce growth in the region.
The rise in Awareness among Health Professionals is Driving Growth in the United States
North America’s prurigo nodularis market accounted for a revenue share of 14.9% in 2022. The United States alone accounted for a revenue share of 13.7% in the same year. Market growth in this region can be attributed to various factors such as:
Presence of Developed Healthcare Industries
Japan is considered to be among the most developed nations which has the presence of various developed healthcare industries that might help in the immediate treatment of prurigo nodularis thus raising the share of the market with a value of 4.0%
Feasible Costs for the Prurigo Nodularis Treatment in India Market
Prurigo Nodularis Treatment in India is considered to be a great choice as the cost of treatment of such a disorder is reasonable in India and people can easily cure it within a proper period, thus raising the market at a CAGR of 3.5%
Economic Growth Helps China to Hold a Leading Position in the Market
Growth in the economy for prurigo nodularis treatment has led to colossal growth in China market at a CAGR of 3.6%
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Capsaicin Cream to Dominate the Market with a Sizable Share
The capsaicin cream segment dominated the prurigo nodularis treatment market by accounting for a revenue share of 40.34% in 2022.
Capsaicin creams serve as a topical remedy for alleviating primary symptoms related to prurigo nodularis. By reducing the activity of pain-related nerve cells in the skin, topical ointment helps alleviate pain in patients suffering from this skin condition.
Increase the popularity of capsaicin in treating prurigo nodularis which may help in driving the growth of the segment. The lack of effective targeted therapy for the disease is further expected to drive gains in this segment during the forecast period.
Retail Pharmacies Leading the Market with a Significant CAGR
Retail pharmacies accounted for a revenue share of 53.10% in 2022, in the prurigo nodularis treatment market.
Growth of the segment is being driven by the increasing preference for obtaining medications from retail pharmacies. Oral or topical medications are the primary treatment option for patients suffering from prurigo nodularis, with surgical procedures being reserved for cases where they are necessary. As a result, patients prefer to obtain their medications from retail pharmacies, which also offer discounts on various medications, further contributing to market growth.
Patients find retail pharmacies to be easily accessible and a convenient option for purchasing their prescribed medications. Unlike specialty pharmacies, patients do not have to wait for their medications to be delivered. They can simply walk into a retail pharmacy and fill their prescription on the spot.
Patients suffering from prurigo nodularis can find a wide range of medications, including corticosteroids, antihistamines, and other topical treatments, at their local retail pharmacy. Competitive pricing offered by retail pharmacies is an added advantage, particularly for patients without health insurance coverage or high deductibles. These factors are expected to propel growth in retail pharmacies in the prurigo nodularis therapeutics market.
Some of the prominent players in the global market
Some of the important developments of the key players in the market are:
| Attribute | Details |
|---|---|
| Growth Rate | CAGR of 3.0% from 2023 to 2033 |
| Market value in 2023 | US$ 693.3 million |
| Market value in 2033 | US$ 930.9 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | US$ million for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customisation Scope | Available on Request |
The North America market may generate a maximum revenue by 2033.
The United States, the United Kingdom, and Germany may witness significant growth in the market.
The growing awareness and better treatment options are expected to drive sales.
Rising research and development may drive market growth over the coming years.
The market recorded a CAGR of 2.8% in 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Corticosteroids
5.3.1.1. Topical
5.3.1.2. Oral
5.3.1.3. Emollients
5.3.1.4. Capsaicin Cream
5.3.1.5. Antihistamines
5.3.1.6. Anticonvulsants
5.3.1.7. Antidepressants
5.3.1.8. Neurokinin 1 Receptor (NK1R)
5.3.1.9. Opiate Receptor Antagonists
5.3.1.10. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The USA
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug Class
15.1.2.2. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug Class
15.2.2.2. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug Class
15.3.2.2. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug Class
15.4.2.2. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug Class
15.5.2.2. By Distribution Channel
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug Class
15.6.2.2. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug Class
15.7.2.2. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug Class
15.8.2.2. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug Class
15.9.2.2. By Distribution Channel
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug Class
15.10.2.2. By Distribution Channel
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug Class
15.11.2.2. By Distribution Channel
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug Class
15.12.2.2. By Distribution Channel
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug Class
15.13.2.2. By Distribution Channel
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug Class
15.14.2.2. By Distribution Channel
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug Class
15.15.2.2. By Distribution Channel
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug Class
15.16.2.2. By Distribution Channel
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug Class
15.17.2.2. By Distribution Channel
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug Class
15.18.2.2. By Distribution Channel
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug Class
15.19.2.2. By Distribution Channel
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug Class
15.20.2.2. By Distribution Channel
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Drug Class
15.21.2.2. By Distribution Channel
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Drug Class
15.22.2.2. By Distribution Channel
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Drug Class
15.23.2.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Bayer AG
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Pfizer Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. GlaxoSmithKline Plc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Teva Pharmaceutical Industries Ltd.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Johnson & Johnson
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Merck & Co. Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Sanofi SA
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Takeda Pharmaceutical Company Limited
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Novartis AG
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Celgene Corporation
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Galderma SA (Nestle Skin Health Company)
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. VYNE Therapeutics Inc.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Prurigo Nodularis Treatment Market
